Studies demonstrated that 2-HG in IDH mutant grade III and IV gliomas neither decreased the differentiation of DCs nor the functionality of differentiated DCs nor interfered with the processing or presentation of DC antigens. This evidence concerns the gene IDH1 and central nervous system cancer.